4 research outputs found
Prognostic factors in treatment for low-grade brain supratentorial infiltrative gliomas
The study showed the results of univariate and multivariate analyses of treatment of patients with low-grade brain supratentorial infiltrative gliomas. It was reaffirmed the importance of the most significance of such adverse prognostic factors as histology, tumor size, displacement of midline structures of the brain, age and neurological deficit. When assessing the prognostic significance of severity of the debut of clinical symptoms in this category of neuro-oncological patients as well as radical surgical treatment of the primary tumor there were obtained data confirming the absence of their independent prognostic significance
Prognostic factors in treatment for low-grade brain supratentorial infiltrative gliomas
The study showed the results of univariate and multivariate analyses of treatment of patients with low-grade brain supratentorial infiltrative gliomas. It was reaffirmed the importance of the most significance of such adverse prognostic factors as histology, tumor size, displacement of midline structures of the brain, age and neurological deficit. When assessing the prognostic significance of severity of the debut of clinical symptoms in this category of neuro-oncological patients as well as radical surgical treatment of the primary tumor there were obtained data confirming the absence of their independent prognostic significance
ΠΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΡΠΈΠΏΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈ ΠΠ’-ΠΠ¦Π
Introduction. Adjuvant systemic therapy remains one of the main options for treating breast cancer. Results of standard immunohistochemical studies are not always a criterion for selecting systemic therapy. Nowadays, multigene expression analysis is actively used to predict the response to chemotherapy in patients with early-stage breast cancer. We studied a 24-gene multi-gene panel for typing breast cancer. Material and Methods. A prospective analysis of 199 breast cancer patients (T1-3N0-3M0) was carried out. Surgical specimens were studied using the standard immunohistochemistry (IHC) and RT-PCR for detecting expression of 24 genes. Results. According to the IHC results, breast cancer was divided into 5 molecular subtypes: luminal A was detected in 59 (30 %) patients; luminal B (HER2-negative) in 52 (26 %); luminal B (HER2-positive) in 19 (9 %); triple-negative in 28 (14 %); HER2-positive 41 (21 %). RT-PCR showed that STK15, MYC, MYBL2, BIRCC5, BCL2, TERT, ESRP1, PGR, HER2, GBR7, MGB1 and MMP11 were the most significant genes in subtype distribution. The total percentage of matches between the two studies was 61.7 %. Conclusion. Studies have shown the need to add additional typing methods for breast cancer to a standard IHC study, which will undoubtedly increase the information content of diagnostic measures and will improve the effectiveness of the treatment.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ΄ΡΡΠ²Π°Π½ΡΠ½Π°Ρ ΡΠΈΡΡΠ΅ΠΌΠ½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΎΡΡΠ°Π΅ΡΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π½Π΅ Π²ΡΠ΅Π³Π΄Π° Π² ΠΏΠΎΠ»Π½ΠΎΠΉ ΠΌΠ΅ΡΠ΅ ΡΠ²Π»ΡΡΡΡΡ ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅ΠΌ Π΄Π»Ρ Π²ΡΠ±ΠΎΡΠ° ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠ»Ρ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠΈ ΡΠ°Π½Π½ΠΈΡ
ΡΡΠ°Π΄ΠΈΡΡ
Π°ΠΊΡΠΈΠ²Π½ΠΎ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΡΡΡ ΠΌΡΠ»ΡΡΠΈΠ³Π΅Π½Π½ΡΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΎΠ½Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ·. ΠΡΠ»Π° ΠΈΠ·ΡΡΠ΅Π½Π° ΠΎΡΠ΅ΡΠ΅ΡΡΠ²Π΅Π½Π½Π°Ρ ΠΌΡΠ»ΡΡΠΈΠ³Π΅Π½Π½Π°Ρ ΠΏΠ°Π½Π΅Π»Ρ, ΡΠΎΡΡΠΎΡΡΠ°Ρ ΠΈΠ· 24 Π³Π΅Π½ΠΎΠ², ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠ°Ρ ΡΠΈΠΏΠΈΡΠΎΠ²Π°ΡΡ ΡΠ°ΠΊ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΡΡ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· 199 Π±ΠΎΠ»ΡΠ½ΡΡ
Π ΠΠ (T1-3N0-3M0), Π² Ρ
ΠΎΠ΄Π΅ ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΠΉ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΏΠΎΠ΄Π²Π΅ΡΠ³Π°Π»ΡΡ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΌΡ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠΌΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΎΠ½ ΠΈΠ·ΡΡΠ°Π»ΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΠ’-ΠΠ¦Π Ρ Π²ΡΡΠ²Π»Π΅Π½ΠΈΠ΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ 24 Π³Π΅Π½ΠΎΠ². Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ ΠΠΠ₯ ΠΎΡΡΡΠ΅ΡΡΠ²Π»ΡΠ»ΠΎΡΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ΅ ΡΠΈΠΏΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π ΠΠ Ρ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ΠΌ 5 ΠΏΠΎΠ΄ΡΠΈΠΏΠΎΠ²: Π»ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΡΠΉ ΡΠΈΠΏ Π Π±ΡΠ» Π²ΡΡΠ²Π»Π΅Π½ Ρ 59 (30 %) Π±ΠΎΠ»ΡΠ½ΡΡ
; Π»ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΡΠΉ Π (HER2-Π½Π΅Π³Π°ΡΠΈΠ²Π½ΡΠΉ) -Ρ 52 (26 %); Π»ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΡΠΉ Π (HER2-ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΠΉ) - Ρ 19 (9 %); ΡΡΠΈΠΆΠ΄Ρ Π½Π΅Π³Π°ΡΠΈΠ²Π½ΡΠΉ - Ρ 28 (14 %); HER2-ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΠΉ - Ρ 41 (21 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°. ΠΠΎ Π΄Π°Π½Π½ΡΠΌ ΠΠ’-ΠΠ¦Π Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π·Π½Π°ΡΠΈΠΌΡΠΌΠΈ Π³Π΅Π½Π°ΠΌΠΈ Π² ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠΈ Π½Π° ΠΏΠΎΠ΄ΡΠΈΠΏΡ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΡΠ²Π»ΡΠ»ΠΈΡΡ: STK15, MYC, MYBL2, BIRCC5, BCL2, TERT, ESRP1, PGR, HER2, GBR7, MGB1 ΠΈ MMP11. ΠΡΠΈ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅ΠΌ Π°Π½Π°Π»ΠΈΠ·Π΅ ΡΡΠΌΠΌΠ°ΡΠ½ΠΎΠ΅ ΡΠΈΡΠ»ΠΎ ΡΠΎΠ²ΠΏΠ°Π΄Π΅Π½ΠΈΠΉ Π΄Π°Π½Π½ΡΡ
Π΄Π²ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΎ 61,7 %. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π»ΠΈ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ Π΄ΠΎΠ±Π°Π²Π»Π΅Π½ΠΈΡ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΡΠΈΠΏΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΠΊ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΌΡ ΠΠΠ₯-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, ΡΡΠΎ, Π½Π΅ΡΠΎΠΌΠ½Π΅Π½Π½ΠΎ, ΠΏΠΎΠ²ΡΡΠΈΡ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΠΎΡΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ ΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ ΠΏΠΎΠ²ΡΡΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠΌΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ
Breast cancer typing using RT-PCR assay [Π²ΠΠΠΠΠΠ½ΠΠ‘Π’ΠΈ Π’ΠΈΠΠΈΡΠΠ²Π°Π½ΠΈΠ― ΡΠ°ΠΠ° ΠΠΠΠΠ§Π½ΠΠΉ ΠΠ΅ΠΠ΅ΠΡ Π‘ ΠΈΠ‘ΠΠΠΡΠΠΠ²Π°Π½ΠΈΠ΅Π ΠΠ΅Π’ΠΠ΄ΠΈΠΠΈ ΠΠ’-ΠΠ¦Ρ]
Introduction. adjuvant systemic therapy remains one of the main options for treating breast cancer. Results of standard immunohistochemical studies are not always a criterion for selecting systemic therapy. Nowadays, multigene expression analysis is actively used to predict the response to chemotherapy in patients with early-stage breast cancer. We studied a 24-gene multi-gene panel for typing breast cancer. Material and Methods. a prospective analysis of 199 breast cancer patients (t1β3N0β3M0) was carried out. surgical specimens were studied using the standard immunohistochemistry (IHc) and Rt-PcR for detecting expression of 24 genes. Results. according to the IHc results, breast cancer was divided into 5 molecular subtypes: luminal a was detected in 59 (30 %) patients; luminal B (HER2-negative) in 52 (26 %); luminal B (HER2-positive) in 19 (9 %); triple-negative in 28 (14 %); HER2-positive 41 (21 %). Rt-PcR showed that stK15, MYc, MYBL2, BIRcc5, BcL2, tERt, EsRP1, PGR, HER2, GBR7, MGB1 and MMP11 were the most significant genes in subtype distribution. the total percentage of matches between the two studies was 61.7 %. Conclusion. studies have shown the need to add additional typing methods for breast cancer to a standard IHc study, which will undoubtedly increase the information content of diagnostic measures and will improve the effectiveness of the treatment. Β© 2019 Tomsk National Research Medical Center of the Russian Academy of Sciences. All rights reserved